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1. Introduction 
Macular edema is a frequent manifestation of diabetic retinopathy and an important cause 
of impaired vision in individuals with diabetes (Klein et al., 1984; Moss et al., 1998). The 
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), a population-based 
study in southern Wisconsin, estimated that after 20 years of known diabetes, the prevalence 
of diabetic macular edema (DME) was approximately 28% in both type 1 and type 2 diabetes 
(Klein, et al., 1984) 
Despite recent attempts at strict glycemic control and optimization of other important 
systemic parameters such as hypertension and hyperlipidemia, diabetic retinopathy 
continues to be a leading cause of new onset vision loss worldwide in the working age 
population (DCCT Group, 1995). Although severe vision loss can occur from proliferative 
diabetic retinopathy (PDR), DME accounts for the majority of vision loss (Moss, et al., 1998).  
Treatment for DME is continuously evolving. While focal laser photocoagulation remains 
the standard of care, a new wave of studies is emerging that shows the benefits of adjunctive 
therapy for DME. The goal of this chapter is to briefly summarize recent strategies for the 
treatment of DME. 
2. Treatment of diabetic macular edema 
DME has been an area of particular interest for clinical investigators. Although PDR is the 
cause of severe vision loss, DME is more prevalent and is the leading cause of moderate 
vision loss in patients with diabetic retinopathy. By disruption of the inner blood–retinal 
barrier, retinal vessels become permeable, leading to the exudation of fluid and lipids into 
the macula, which ultimately leads to a decline in vision (Bhagat et al., 2009). 
The Early Treatment for Diabetic Retinopathy Study (ETDRS) was the first randomized and  
controlled trial to examine therapy for DME, and it demonstrated that focal (direct/grid) 
laser photocoagulation reduces moderate vision loss caused by DME by 50% or more 
(ETDRS group, 1987a). The ETDRS also indicated that focal laser treatment is not an ideal 
therapy. Focal laser treatment failed to prevent vision loss in a large number of patients, and 
it did not improve vision in the majority of patients (ETDRS group, 1985).  
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2.1 Laser treatment 
Laser photocoagulation remains the standard of care and the only treatment with proven 
efficacy in a large-scale clinical trial for this condition. The ETDRS demonstrated the efficacy 
of focal/grid photocoagulation in reducing the risk of moderate vision loss from DME 
(ETDRS group, 1991). The beneficial outcomes of focal/grid laser in an era of improved 
glycemic control were confirmed and expanded in recent clinical trials conducted by the 
Diabetic Retinopathy Clinical Research Network (DRCR.net) (Aiello et al., 2010; Beck et al., 
2009; DRCR net, 2008).  
Focal/grid photocoagulation has potential side effects, including laser scar expansion, 
paracentral scotomata, elevation of central visual field thresholds, and secondary choroidal 
neovascularization and subretinal fibrosis (Guyer et al., 1992; Han et al., 1992; Schatz et al., 
1991). Modifications to the focal/grid photocoagulation technique have been made in 
response to these potential side effects. A comparison across studies suggests that outcomes 
with current modified techniques may be similar to those obtained with the original ETDRS 
technique (DRCR net, 2009). 
2.1.1 Focal / grid laser photocoagulation 
To characterize the severity of macular edema and for treatment guidelines, the term 
clinically significant macular edema (CSME) is defined: retinal thickening at or within 
500μm of the foveal center, hard exudates at or within 500μm of the foveal center with 
adjacent retinal thickening, or retinal thickening greater than 1 disc diameter in size, within 
1 disc diameter of the foveal center (ETDRS group, 1985, 1987a). 
There is good evidence that focal laser treatment preserves vision in eyes with DME. The 
ETDRS randomized 1490 eyes with DME to receive focal laser treatment or observation 
(ETDRS group, 1985). Retreatment was applied at 4-month intervals if CSME persisted, one 
or more treatable lesions were identified, and the investigator believed these lesions were 
responsible for the edema (ETDRS group, 1987b). At 3 years, treatment significantly reduced 
moderate visual loss as compared with observations, with the greatest benefits in eyes with 
CSME (ETDRS group, 1987b) 
Although focal laser photocoagulation reduces the risk of moderate visual loss by 
approximately 50%, approximately 12% of treated eyes still lose vision, many because of 
persistent DME (ETDRS group, 1985). Kim et al. assessed macular optical coherence 
tomography (OCT) findings of DME patients to determine whether specific OCT patterns 
are predictive of visual outcome after focal laser photocoagulation (Kim et al., 2009). DME 
was classified into four different OCT patterns, which are: diffuse retinal thickening, 
cystoids macular edema, serous retinal detachment, and vitreomacular interface 
abnormalities (Figure 1). In this study, eyes with diffuse retinal thickening achieved a 
greater visual acuity increase than eyes with other patterns. 
It is unclear how focal retinal laser exerts its effects. One theory is that it improves 
oxygenation to the inner retina by eliminating highly oxygen-dependent photoreceptors 
(Gottfredsdottir et al., 1993; Stefansson, 2001). Another theory is that the laser reduces the 
retinal capillary area and thereby reduces leakage (Wilson et al., 1988). Other authors 
postulate that photocoagulation restores the outer blood–retinal barrier (Bresnick, 1983). 
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Fig. 1. Different patterns of diabetic macular edema by optical coherence tomography. (A) 
Diffuse retinal thickening appears as a sponge-like retinal swelling with areas of reduced 
intraretinal reflectivity. (B) Cystoid macular edema showing intraretinal cystoid spaces. (C) 
Serous retinal detachment showing shallow elevation of the retina, with an optically clear 
space between the retina and the retinal pigment epithelium. (D) Vitreomacular interface 
abnormalities showing a highly reflective band over the inner retinal surface and extending 
towards the optic nerve or peripherally. 
2.1.2 Modified ETDRS direct/grid photocoagulation 
Although effective, ETDRS protocol for photocoagulation may require placement of burns 
close to the center of the macula. Over time, laser burns may develop into areas of 
progressive retinal pigment epithelium and retinal atrophy that become larger than the 
original laser spot size and this may encroach upon fixation (Schatz, et al., 1991). In an 
attempt to reduce these adverse effects, many retinal specialists now treat patients using 
burns that are lighter and less intense than what was originally specified in the ETDRS, 
although no clinical trials have been performed to show improved outcomes with this 
approach (Akduman & Olk, 1999). 
These include specifications with maximal spot sizes of 50μm, allowing the use of yellow 
and green wavelengths, not requiring blanching of large microaneurysms as long as the 
subjacent retinal pigment epithelium is lightly blanched, and removing the requirement for 
fluorescein angiography to guide treatment (Abu el Asrar & Morse, 1991; Fong et al., 2007). 
A modified ETDRS focal/grid photocoagulation protocol including all these changes has 
been adopted as the standard laser technique for DME used in DRCR Network studies. 
2.1.3 Mild Macular Grid (MMG) laser photocoagulation 
An alternative approach is the mild macular grid (MMG) technique, the application of mild, 
widely spaced burns throughout the macula (avoiding the foveal region). By design, some 
burns could be placed in clinically normal appearing retina if the entire retina was not 
www.intechopen.com
 
Diabetic Retinopathy 
 
276 
abnormally thickened, including areas within the macula that are relatively distant from the 
area of thickening. The lighter burns applied to the macula are theoretically less likely to 
result in thermal injury to the overlying retina and less likely to break the Bruch membrane. 
The widespread application also might lead to improved oxygenation, development of 
healthier retinal pigment epithelium, and overall physiologic improvement of the entire 
macula.  
The DRCR Network trial was designed to compare 2 laser techniques for previously 
untreated DME. One technique was the most commonly used approach in current clinical 
practice, the modified ETDRS technique, and the other approach was the MMG technique. 
At 12 months after treatment, the MMG technique was less effective at reducing OCT–
measured retinal thickening than the current modified ETDRS laser photocoagulation 
approach. The visual acuity outcomes with both approaches were not substantially 
different. (Fong, et al., 2007).  
2.1.4 Subthreshold Micropulse Diode Laser Photocoagulation (SMDLP) 
Many laser modalities such as argon blue-green, argon green, krypton and diode have been 
used to achieve a clinically visible burn (threshold burn) according to the conventional 
photocoagulation protocol (Akduman & Olk, 1997; Olk, 1990). Subthreshold micropulse 
diode laser photocoagulation (SMDLP) is designed to target the retinal pigment epithelium 
while minimizing the negative thermal effects on the neural retina and deeper structures. A 
micropulse diode laser allows subthreshold therapy without a visible burn end point, and 
has been shown to be as effective as standard argon laser photocoagulation in reducing 
DME, while potentially allowing for more frequent re-dosing (Jain et al., 2010).  
A study comparing the efficacy and side effects of conventional green laser photocoagulation 
and SMDLP treatment for diabetic CSME was conducted with prospective, randomized, 
double-masked manner. There were no statistically significant differences in best-corrected 
visual acuity (BCVA), contrast sensitivity and retinal thickness between the two laser 
modalities at 0, 4 and 12 months. It is found that laser scarring was much more apparent with 
conventional green laser than with the SMDLP (Figueira et al., 2009). 
Recently, Lavinsky et al. conducted a prospective, randomized, controlled, double-masked 
clinical trial comparing modified ETDRS focal/grid laser photocoagulation with normal-
density or high-density SMDLP for the treatment DME. In this study, the subthreshold 
micropulse 810-nm diode laser technique delivered in a high-density manner was superior 
to the standard mETDRS photocoagulation over at least 1 year of follow-up, with 
significantly more eyes gaining substantial vision and significantly fewer eyes losing 
substantial vision. (Lavinsky et al., 2011). 
2.2 Steroid treatment 
Corticosteroids are potent anti-inflammatory agents that can counteract many of the 
pathological processes thought to play a role in the development of macular edema. 
Corticosteroids prevent leukocyte migration, reduce fibrin deposition, stabilize endothelial 
cell tight junctions, and inhibit synthesis of vascular endothelial growth factor (VEGF), 
prostaglandins, and proinflammatory cytokines (Joussen et al., 2007; Kern, 2007; Leopold, 
1985; Nauck et al., 1998). 
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The rationale for the use of corticosteroids to treat DME follows from the observation that 
the increase in retinal capillary permeability that results in edema may be caused by a 
breakdown of the blood retina barrier mediated in part by VEGF (Aiello et al., 1997; 
Antonetti et al., 1999; Senger et al., 1983). Corticosteroids have been demonstrated to inhibit 
the expression of VEGF and the VEGF gene (Nauck, et al., 1998; Nauck et al., 1997).  
2.2.1 Intravitreal triamcinolone 
In 2001-2002, the first reports were published of the use of intravitreal injection of 
triamcinolone acetonide for DME (Jonas & Sofker, 2001; Martidis et al., 2002), suggesting 
that intravitreal triamcinolone was potentially an efficacious treatment for DME. This 
treatment gained widespread use, most commonly as a dose of 4 mg of Kenalog® (Bristol-
Myers Squibb, Princeton NJ), despite the lack of data from a controlled study demonstrating 
efficacy that exceeded risks.  
In light of the short-term results from early reports of intravitreal triamcinolone for DME, 
the DRCR Network conducted a randomized clinical trial to evaluate the efficacy and safety 
of two doses of preservative-free intravitreal triamcinolone (1 mg and 4 mg) in comparison 
with standard focal/grid photocoagulation. At 4 months, both triamcinolone groups had 
greater improvement in visual acuity and macular thickness than the focal laser; however, 
by year one, there was no difference between the groups, and by the second year, the laser 
group demonstrated better visual acuity and more reduced macular thickness results over 
the corticosteroid groups (DRCR net, 2008). Another study in a subset of randomized 
subjects who completed the 3-year follow-up do not indicate a long-term benefit of 
intravitreal triamcinolone relative to focal/grid photocoagulation in patients with DME 
similar to those studied in this clinical trial (Beck, et al., 2009). 
More recently, Gillies et al. reported that treatment with intravitreal triamcinolone acetonide 
plus laser resulted in a doubling of improvement in vision by 10 letters or more compared 
with a laser only over 2 years in eyes with DME. However, this treatment was associated 
with cataracts and a raised intraocular pressure (Gillies et al., 2011)  
2.2.2 Peribulbar triamcinolone 
Peribulbar injections have been performed using anterior combined sub-Tenon and 
subconjunctival, posterior sub-Tenon, and retrobulbar approaches. Theoretically, adverse 
effects may be presumed to be lower than those of intravitreal triamcinolone acetonide. A 
peribulbar corticosteroid injection is of particular interest for eyes with DME that have good 
visual acuity where the risks of an intravitreal injection of corticosteroid may not be justified 
(E. Chew et al., 2007).  
The DRCR Network conducted a pilot study evaluating the effects of both anterior and 
posterior sub-Tenon delivery of peribulbar corticosteroids, with or without focal 
photocoagulation, in eyes with DME and good visual acuity. In cases of DME with good 
visual acuity, peribulbar triamcinolone, with or without focal photocoagulation, is unlikely 
to be of substantial benefit (E. Chew, et al., 2007). The group further reported long-term 
effects of anterior and posterior peribulbar injections of triamcinolone acetonide. The results 
suggested that the risk of intraocular pressure elevation and cataract development is 
increased with anterior peribulbar triamcinolone acetonide injections while ptosis 
development is increased with the posterior peribulbar injections (E. Y. Chew et al., 2011). 
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2.2.3 Dexamethasone implant 
The treatment of macular edema is considerably limited by the difficulty in delivering 
effective doses of therapeutic agents into the vitreous cavity. In recent years, the 
development of a sustained-release intravitreal dexamethasone implant (Ozurdex® , 
Allergan Inc, Irvine, CA) enabled more controlled delivery of the drug, with a potentially 
lower rate of adverse events (Herrero-Vanrell et al., 2011). 
In a previous study to evaluate the safety and efficacy of dexamethasone implant vs. 
observation in eyes with persistent DME, treatment with a 700μg intravitreal 
dexamethasone drug delivery system is well tolerated and produces significant 
improvements in BCVA, central retinal thickness, and fluorescein leakage, compared with 
observation (Haller, Kuppermann, et al., 2010). 
2.2.4 Fluocinolone acetonide 
Extended release intravitreal inserts of fluocinolone acetonide have also been evaluated for 
the treatment of DME. As fluocinolone acetonide has been in use for many years as a dermal 
product, its pharmacology, systemic metabolism and elimination are well established.  
A nonbiodegradable fluocinolone acetonide, Retisert® (Bausch & Lomb, Rochester, NY) is 
FDA-approved for the treatment of uveitis. Surgical implantation of this polymer device 
initially showed evidence of benefit in reducing macular thickness in DME; however 20% of 
patients required filtering surgery for high intraocular pressures within 24 months (Pearson 
et al., 2005).  
Iluvien® (Alimera Sciences, Alpharetta, GA) is another reservoir implant currently being 
studied in phase III trials for the treatment of DME. It was hypothesized that fluocinolone 
acetonide inserts may cause fewer problems with glaucoma than the surgically implanted 
device because of lower in vitro release rates of fluocinolone acetonide (0.2 and 0.5μg/day) 
and also because of a more posterior location in the eye, which may decrease exposure to 
the trabecular meshwork in the anterior chamber while still delivering adequate levels of 
fluocinolone acetonide to the retina. In a small phase II trial in patients with persistent DME 
despite focal laser, both 0.2- and 0.5-μg/day fluocinolone acetonide inserts significantly 
improved visual acuity in patients with DME over 2 years. Significantly fewer incisional 
glaucoma procedures were needed in the low-dose insert group (Campochiaro et al., 2010). 
2.3 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) injection 
An alternative treatment approach, and to now, available for less than a decade, is the use of 
intravitreal therapies targeting VEGF (Nicholson & Schachat, 2010), the most potent known 
promoter of vascular permeability (Senger et al., 1990). Clinical studies have established that 
VEGF concentrations are elevated in eyes with DME (Funatsu et al., 2003; Funatsu et al., 
2005), and preclinical studies have demonstrated that VEGF levels increased after its onset 
in a manner temporally correlated with the breakdown of the blood–retinal barrier (Qaum 
et al., 2001). Several mechanisms are believed to underlie these actions; in addition to the 
direct action of VEGF on the permeability of intact blood vessels, it also promotes an influx 
of inflammatory cells that produces endothelial cell apoptosis in the retinal vasculature 
(Adamis & Berman, 2008).  
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2.3.1 Pegaptanib 
Pegaptanib (Macugen®; Eyetech Pharmaceuticals, Inc. and Pfizer Inc, New York) is a 
ribonucleic acid aptamer that targets the VEGF165 isoform that is currently approved in a 
number of countries worldwide for the treatment of neovascular age-related macular 
degeneration. 
Cunningham et al. assessed the efficacy of pegaptanib for the treatment of DME. In a phase 
II trial, subjects treated with pegaptanib had better visual acuity outcomes, were more likely 
to show a reduction in central retinal thickness, and were deemed less likely to need 
additional therapy with photocoagulation at follow-up than those assigned to sham 
injection (Cunningham et al., 2005). 
A phase 2/3, randomized, double-masked, 2-year trial has been performed to assess the 
safety and efficacy of intravitreal pegaptanib sodium 0.3 mg compared with sham injections 
in subjects with DME, with focal/grid photocoagulation being permitted as needed after 
week 18. In this study, intravitreal pegaptanib sodium 0.3 mg was well tolerated and 
demonstrated superior efficacy over the sham in the treatment of patients with DME. The 
proportion of patients with ≥10 letters (or 2 lines) of visual acuity improvement at week 54 
was statistically significantly greater in the pegaptanib group versus those in the sham 
treatment arm (P = 0.0047; primary efficacy endpoint) (Sultan et al., 2011). 
2.3.2 Ranibizumab 
Ranibizumab (Lucentis®; Genentech, South San Francisco, California) is a humanized 
antibody fragment directed at all isoforms of VEGF-A and is fabricated specifically for 
intravitreal use. Ranibizumab is now FDA-approved for the treatment of age-related 
macular degeneration as well as macular edema associated with retinal vein occlusion. 
For diabetic macular edema, an initial small pilot study showed efficacy of intravitreal 
injections of ranibizumab in reducing macular thickness and improving visual acuity 
(Nguyen et al., 2006).  
Acting upon the favorable results of their pilot study, a 6-month, phase II, multicenter, 
randomized controlled trial, the Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-
2) study was designed. Patients with DME were randomized to three groups. Group 1 
received four injections of ranibizumab, group 2 received focal laser at baseline and again at 3 
months if needed; and group 3 had combination of laser treatment and injections of 
ranibizumab. The ranibizumab only group gained a mean of 7.24 ETDRS letters, the laser-only 
group lost 0.43 letters, and the combination group had gained 3.80 letters (Nguyen et al., 2009).  
Data at twenty-four-months were also reported for the READ-2 study. After the initial 6 
months, all patients were followed up every 2 months. Patients in group 1 could be re-
injected if they had persistent or recurrent DME, patients in group 2 could receive 
ranibizumab alone or laser only, and patients in group 3 could receive ranibizumab alone or 
in combination with laser. After 24 months, patients gained 7.7, 5.1, and 6.8 letters in the 
three groups, respectively, and the percentage of patients who gained three or more lines of 
visual acuity was 24, 18 and 26%, respectively (Nguyen et al., 2010). 
One-year safety and efficacy results from the Ranibizumab in Diabetic Macular Edema 
Study (RESOLVE) have also been reported. This was a phase II, randomized clinical trial 
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comparing 0.3 and 0.5mg ranibizumab with sham injections for the treatment of DME in 151 
eyes. Patients received three monthly injections initially, followed by continuation of 
monthly injections on an as-needed basis with the opportunity for rescue focal laser 
treatment. In addition, after the first month, dose doubling (0.05 to 0.10 ml) was allowed 
based on pre-specified criteria. At the end of the 12-month assessment period, ranibizumab 
led to a mean gain of 10.3 letters from the baseline compared with a decline of 1.4 letters in 
the sham patients. Macular thickness reduction was also greater in the ranibizumab group 
vs. the sham group (Massin et al., 2010). 
The DRCR Network group has reported 1-year results of a phase III, randomized controlled 
trial comparing four groups: sham injection plus prompt laser, ranibizumab plus prompt 
laser, ranibizumab plus deferred laser, and triamcinolone plus prompt laser. A total of 854 
eyes of 691 patients were enrolled. In the ranibizumab groups, patients received at least four 
initial injections, after which retreatment was based on specific retreatment criteria. Change 
in mean visual acuity was greater in both ranibizumab groups (both +9 letters) vs. the laser 
only (+3 letters) and the triamcinolone group (+4 letters). Reduction in macular thickness 
was similar in all three injection groups and was greater than that in the laser only group 
(Elman et al., 2010).  
The expanded 2-year results reported are similar to the results published previously and 
reinforce the conclusions originally reported. At the 2-year visit, compared with the sham 
plus prompt laser group, the mean change in the visual acuity letter score from the baseline 
was 3.7 letters greater in the ranibizumab plus prompt laser group, 5.8 letters greater in the 
ranibizumab plus deferred laser group, and 1.5 letters worse in the triamcinolone plus 
prompt laser group (Elman et al., 2011).  
The 12-month, phase III, randomized, double-masked, multicenter, laser-controlled 
RESTORE study was designed to assess whether ranibizumab monotherapy or combined 
with laser was superior to laser alone in patients with visual impairment due to DME. The 
results from the RESTORE study demonstrated that treatment with ranibizumab as a 
monotherapy and combined with laser treatment is superior to laser treatment in rapidly 
improving and sustaining visual acuity in patients with visual impairment due to DME. 
There were no efficacy differences detected between the ranibizumab and ranibizumab 
combined with laser treatment arms (Mitchell et al., 2011). 
2.3.3 Bevacizumab 
Bevacizumab (Avastin®; Genentech, South San Francisco, California) inactivates all VEGF 
isoforms and is indicated for systemic use as an adjunct cancer chemotherapeutic agent (Van 
Meter & Kim, 2010). Bevacizumab, which is a full-length humanized monoclonal G1 
antibody, has emerged as a therapeutic agent for retinal diseases (Arevalo et al., 2009), and 
has been used as an off-label agent in a number of ocular diseases, including diabetic 
retinopathy (Gunther & Altaweel, 2009).  
The DRCR Network group conducted a phase II study over 3 months in 121 eyes, 
comparing five treatment arms: focal photocoagulation, two intravitreal injections of 1.25mg 
bevacizumab, two intravitreal injections of 2.5mg bevacizumab, one 1.25mg bevacizumab 
followed by a sham injection at week 6, and two 1.25mg bevacizumab injections combined 
with focal photocoagulation. Compared with laser alone, eyes in groups 2 and 3 had an 
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improvement in visual acuity after 3 months (-1 letter vs. +5 and +7 letters, respectively). 
There was a greater initial reduction in macular thickness after 3 weeks in groups 2 (-35μm) 
and 3 (-86μm) compared with laser (+21μm); however, this difference did not persist by 
week 12 (Scott et al., 2007).  
A subsquent 3-arm randomized clinical trial demonstrated the superiority of intravitreal 
bevacizumab injection either alone or in combination with triamcinolone acetonide over 
macular laser photocoagulation in visual acuity improvement up to 24 weeks in primary 
treatment of DME. This improving effect persisted longer in the intravitreal bevacizumab 
group (up to 36 weeks) than in the intravitreal bevacizumab/intravitreal triamcinolone 
acetonide group (up to 12 weeks). In the macular laser photocoagulation group, no 
improvement in visual acuity was observed at all follow-up visits. In regard to central 
macular thickness reduction, there was no meaningful superiority of the intravitreal 
bevacizumab and intravitreal bevacizumab/intravitreal triamcinolone groups over the 
macular laser photocoagulation group (Soheilian et al., 2009). 
The intravitreal Bevacizumab or Laser Therapy in the management of diabetic macular 
edema study (BOLT) was designed to compare bevacizumab therapy to laser for DME. This 
study was a randomized controlled trial comparing intravitreal bevacizumab 1.25mg with 
laser therapy in 80 patients who had previously received focal laser for DME. Patients in the 
bevacizumab arm received injections every 6 weeks for the first 3 months and every 6 weeks 
as needed thereafter, while those in the laser group received as needed laser every 4 months. 
The bevacizumab arm had superior visual acuity results at 12 months (+8 vs. -0.5 letters), a 
5.1 times greater odds of gaining at least 10 letters, and a trend toward greater decrease in 
macular thickness (130 vs. 68μm) (Michaelides et al., 2010). 
2.3.4 VEGF-Trap  
VEGF Trap-Eye® (Regeneron Pharmaceuticals., Tarrytown, New York, NY, and Bayer 
Healthcare Pharmaceuticals, Berlin, Germany) is a 115-kDA recombinant fusion protein 
consisting of the VEGF binding domains of human VEGF receptors 1 and 2 fused to the Fc 
domain of human immunoglobulin-G1 (Holash et al., 2002). Animal studies have 
demonstrated that intravitreal VEGF Trap-Eye has theoretic advantages over ranibizumab 
and bevacizumab, including a longer half life in the eye and a higher binding affinity to 
VEGF-A (Gaudreault et al., 2005). In addition, the fusion protein binds placental growth 
factors 1 and 2, which have been shown to contribute to excessive vascular permeability and 
retinal neovascularization (Rakic et al., 2003).  
A phase I study showed that a single intravitreal injection of VEGF Trap-Eye effected 
biological activity by improving visual acuity and reducing excess retinal thickness in 5 eyes 
with DME (Do et al., 2009).  
On the basis of a sound biological rationale and encouraging phase I results, a phase II 
multicenter, randomized clinical trial, the DME and VEGF Trap-Eye: INvestigation of 
Clinical Impact (DA VINCI) study was designed to compare intravitreal VEGF Trap-Eye 
with standard macular laser treatment after the modified ETDRS protocol. In this phase II 
randomized clinical trial, intravitreal VEGF Trap-Eye was superior to macular laser 
treatment by the modified ETDRS protocol for the treatment of DME over a 24-week period. 
VEGF Trap-Eye resulted in significantly better mean visual acuity outcomes (+8.5 to +11.4 
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vs. +2.5 letters gained) and greater mean reductions in retinal thickness (-127.3 to -194.5μm 
vs. -67.9μm) compared with laser alone (Do et al., 2011). 
2.4 Vitrectomy 
The vitreous has been implicated as a cause of macular edema in people with diabetes via 
several mechanical and physiologic mechanisms, all of which are postulated to lead to 
increased vascular permeability. Widespread or diffuse DME that is unresponsive to focal 
laser treatment may benefit from a vitrectomy. The presence of vitreous traction and 
macular edema, now readily documented with OCT, in association with visual impairment 
is also a common indication for the need of a vitrectomy. Complications of vitrectomy 
include recurrent vitreous hemorrhage, retinal tears and detachment, cataract formation and 
glaucoma (Figueroa et al., 2008; Harbour et al., 1996; Hartley et al., 2008; Ikeda et al., 1999; 
Lewis et al., 1992; Pendergast et al., 2000; Tachi & Ogino, 1996; Yamamoto et al., 2001). 
In a prospective study of 87 eyes undergoing vitrectomy for DME associated with at least 
moderate visual loss and vitreomacular traction, the median change in visual acuity at 6 
months was an improvement of 3 letters, with visual acuity improving by ≥ 10 letters from 
the baseline to 6 months in 38% and worsening by ≥ 10 letters in 22%. Reduction in OCT 
central subfield thickness to < 250μm occurred in almost half, and most eyes had a reduction 
of thickening of ≥ 50% (Haller, Qin, et al., 2010). 
2.5 Protein kinase C inhibitor 
An increased understanding of the pathophysiology of diabetic microangiopathy and the 
mechanisms of glycaemic vascular damage might facilitate the development of new 
therapeutic agents that ameliorate microvascular complications, even or especially when 
tight glycaemic control is unattainable. Hyperglycaemia-induced de novo synthesis of 
diacylglycerol in vascular cells leads to preferential activation of the PKC-β isoform, which 
is strongly implicated in the pathogenic processes involved in diabetic microangiopathy 
such as ischemia, leakage, neovascularization and abnormal vasodilator function (Idris & 
Donnelly, 2006). 
2.5.1 Protein kinase C β inhibitor (Ruboxistaurin) 
The Protein Kinase C β inhibitor Diabetic Retinopathy Study (PKC-DRS) was designed to 
test the primary hypothesis that ruboxistaurin, a β-isoform–selective protein kinase C 
inhibitor, would delay the progression of diabetic retinopathy. Ruboxistaurin was well 
tolerated without significant adverse effects. Compared with a placebo, 32 mg/day 
ruboxistaurin was associated with a delayed occurrence of moderate visual loss. However, 
in patients with moderately severe to very severe nonproliferative diabetic retinopathy at 
the baseline, ruboxistaurin did not prevent retinopathy progression to the proliferative 
disease state (PKC-DRS group, 2005). 
2.5.2 PKC412 
Orally administered PKC412 at doses of 100mg/day or higher may significantly reduce 
macular edema and improve visual acuity in diabetic subjects. However, concern regarding 
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liver toxicity with systemic therapy makes local delivery an appealing approach 
(Campochiaro, 2004). 
2.6 Others 
2.6.1 HMG-CoA reductase inhibitor (Atorvastin) 
Lipids have a definite role in the pathogenesis of diabetic retinopathy. Because of the 
increased permeability and leakage of the retinal capillaries, extravascular deposition of less 
soluble plasma lipoprotein occurs. The mass of lipid-filled macrophages is visible on 
funduscopy as hard exudates (Watanabe et al., 1988).  
Statins act by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase, the first committed enzyme of the HMG-CoA reductase pathway. Sen et al. 
found that statins retard the progression of retinopathy in patients with diabetes mellitus 
and hypercholesterolemia (Sen et al., 2002), whereas other studies have reported that statins 
limit the severity of hard exudates and subfoveal lipid migration in CSME (Gordon et al., 
1991; Gupta et al., 2004). 
A recent study evaluated the efficacy and safety of atorvastatin and described its effect on 
hard exudates and macular edema in patients with diabetes mellitus and dyslipidemia. In 
this study, aggressive treatment of hyperlipidemia resulted in significant improvement in 
hard exudates and fluorescein leakage. The lipid-lowering drug atorvastatin was safe when 
administered to patients with diabetes mellitus and useful in the management of DME in 
patients with an abnormal lipid profile (Panagiotoglou et al., 2010). 
3. Conclusion 
Although, focal laser photocoagulation is the standard-of-care treatment for DME, it is not a 
cure. During the last decade, a number of additional treatments for DME have been 
proposed. Such treatments include intravitreal injection of corticosteroids such as 
triamcinolone acetonide, intravitreal injection of aptamers or antibodies targeted at VEGF, 
vitrectomy, and pharmacologic therapy with oral protein kinase C beta inhibitors.  
In particular, anti-VEGF therapies, in conjunction with laser or as standalone treatments, 
have shown promise in not only maintaining but also improving visual acuity. Intravitreal 
triamcinolone also has a role in treating patients with DME refractory to laser and anti-
VEGF therapy, and it remains to be seen whether extended-release corticosteroid devices 
might play a role in the management of DME. Diabetic patients with macular edema who 
have a taut posterior hyaloid membrane may benefit from pars plana vitrectomy and 
removal of the posterior hyaloids  
The pathogenesis of DME is complex, and a variety of factors and biochemical pathways are 
involved, which provides an opportunity for the development of a number of therapeutic 
modalities to treat the condition.  
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